We expect Impel NeuroPharma Inc (IMPL) stock to go up on 7 July Friday based on our mathematical analysis model.
Related News:
Impel Pharmaceuticals Announces It Will Present New Real-World Data for Trudhesa® at the American Headache Society’s 65th Annual Scientific Meeting
Impel Pharmaceuticals has announced that it will present new real-world data that adds to the growing body of evidence supporting Trudhesa® (dihydroergotamine mesylate [DHE]) Nasal Spray (0.725 mg per spray) as a effective acute treatment for the management of migraine. These results will be the subject of two poster presentations at the 65th Annual Scientific Meeting of the American Headache Society (AHS), to be held June 15-18, 2023 in Austin, Texas. Preliminary results from an evaluation of medical and pharmaceutical data for migraine patients treated with Trudhesa in the United States provide new evidence suggesting that the concomitant use of preventive medications (with the exception of the class of monoclonal antibodies anti- CGRP) and acute generally decreases in patients treated with Trudhesa between the 12-month baseline and the 90-day follow-up period.
It is important to note that no increase in anti-nausea drugs was observed after using Trudhesa, whereas these drugs are commonly used when DHE is given intravenously. A second poster on actual demographic and clinical characteristics, as well as baseline comorbidities in migraine patients treated with Trudhesa, revealed that most patients were female between the ages of 36 and 45 and had comorbidities such as as headache syndromes other than migraine, other neurological disorders, other pain disorders, sleep disorders, gastrointestinal (GI) disorders and psychiatric disorders. In contrast to other epidemiological studies, in this real-world patient population, gastrointestinal comorbidities were more common, which may be explained by the fact that many of these patients fail to achieve migraine relief. orally.
Trudhesa uses Impel’s proprietary Precision Olfactory Delivery (POD®) technology and is the first and only migraine nasal spray that rapidly delivers DHE u a proven and proven migraine treatment u into the bloodstream through upper nasal space rich in vessels. Trudhesa bypasses the gut and reduces potential absorption issues, providing fast, long-lasting and consistent symptom relief without the nausea commonly associated with DHE u injection or infusion, even when administered several hours later. the onset of a migraine attack.